Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR

Diabetes care1 Jan 2003Cited by 104 (Europe PMC)

PMID12502651DOI10.2337/diacare.26.1.1PepBankPUB-12502651

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanNon-randomized trialEfficacy outcome
In type 1 diabetes using insulin pumps, hyperglycemic readings fell from 59% at baseline to 48% with pramlintide.
In plain wordsIn type 1 diabetes using insulin pumps, high glucose readings decreased with pramlintide versus baseline.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHyperglycemic readings
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeksAs given in this study (human).
Measurements
CGMS readings >140 mg/dl
59%
baseline
CGMS readings >140 mg/dl
48%
after 4 weeks on pramlintide
Source sentences
Summary
After 4 weeks on pramlintide, measurements in the hyperglycemic range declined to 48% and measurements within the euglycemic range increased to 37%.
2 context sentences(design, population, supporting numbers)
Summary · context
At baseline, patients had excessive 24-h glucose fluctuations, with 59% of the CGMS measurements >140 mg/dl, 13% <80 mg/dl, and only 28% in the euglycemic range (80-140 mg/dl).
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265101
02HumanNon-randomized trialEfficacy outcome
In type 1 diabetes using insulin pumps, euglycemic readings increased from 28% at baseline to 37% with pramlintide.
In plain wordsIn type 1 diabetes using insulin pumps, glucose readings within the target range increased with pramlintide versus baseline.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseEuglycemic readings
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeksAs given in this study (human).
Measurements
CGMS readings 80-140 mg/dl
28%
baseline
CGMS readings 80-140 mg/dl
37%
after 4 weeks on pramlintide
Source sentences
Summary
After 4 weeks on pramlintide, measurements in the hyperglycemic range declined to 48% and measurements within the euglycemic range increased to 37%.
2 context sentences(design, population, supporting numbers)
Summary · context
At baseline, patients had excessive 24-h glucose fluctuations, with 59% of the CGMS measurements >140 mg/dl, 13% <80 mg/dl, and only 28% in the euglycemic range (80-140 mg/dl).
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265102
03HumanNon-randomized trialEfficacy outcome
In type 1 diabetes using insulin pumps, mealtime insulin dosages were 17% lower during pramlintide treatment, with boluses reduced per protocol.
In plain wordsIn type 1 diabetes using insulin pumps, mealtime insulin doses were 17% lower during pramlintide treatment, as planned in the study.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMealtime insulin dose
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeksAs given in this study (human).
Measurements
Reduction in mealtime insulin dosage
17%
after 4 weeks on pramlintide
Source sentences
Summary
This shift from the hyperglycemic to the euglycemic range occurred with a concomitant 17% reduction in mealtime insulin dosages and without relevant increases in measurements below the euglycemic range (15%) or any severe hypoglycemic events.
2 context sentences(design, population, supporting numbers)
Summary · context
Mealtime insulin boluses were reduced by a minimum of 10% during the first 3 days, and re-adjusted thereafter based on clinical judgment.
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265103
04HumanNon-randomized trialSafety outcome
In type 1 diabetes using insulin pumps, below-range readings showed no relevant increase with pramlintide and reached 15%.
In plain wordsIn type 1 diabetes using insulin pumps, low glucose readings showed no relevant increase with pramlintide versus baseline.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeBelow-range glucose readings
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeksAs given in this study (human).
Measurements
CGMS readings <80 mg/dl
15%
after 4 weeks on pramlintide
Source sentences
Summary
This shift from the hyperglycemic to the euglycemic range occurred with a concomitant 17% reduction in mealtime insulin dosages and without relevant increases in measurements below the euglycemic range (15%) or any severe hypoglycemic events.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265104
05HumanNon-randomized trialSafety outcome
In type 1 diabetes using insulin pumps, no severe hypoglycemic events occurred during pramlintide treatment.
In plain wordsIn type 1 diabetes using insulin pumps, no severe low blood sugar events occurred during pramlintide treatment.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableSevere hypoglycemia
Study
n = 16
Outcome group
Adverse events · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeksAs given in this study (human).
Source sentences
Summary
This shift from the hyperglycemic to the euglycemic range occurred with a concomitant 17% reduction in mealtime insulin dosages and without relevant increases in measurements below the euglycemic range (15%) or any severe hypoglycemic events.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265105
06HumanNon-randomized trialEfficacy outcome
In type 1 diabetes using insulin pumps, pramlintide reduced postprandial glucose excursions by approximately 86% versus baseline.
In plain wordsIn type 1 diabetes using insulin pumps, pramlintide reduced glucose rises after meals versus baseline.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose excursion
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeksAs given in this study (human).
Measurements
Postprandial glucose excursion reduction (incremental AUC)
≈ 86%
after 4 weeks on pramlintide versus baseline
Source sentences
Summary
After 4 weeks on pramlintide, postprandial glucose, glucagon, and triglyceride excursions were reduced by approximately 86, approximately 87, and approximately 72%, respectively (incremental areas under the curve, all P < 0.05 vs. baseline).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265106
07HumanNon-randomized trialMechanism
In type 1 diabetes using insulin pumps, pramlintide reduced postprandial glucagon excursions by approximately 87% versus baseline.
In plain wordsIn type 1 diabetes using insulin pumps, pramlintide reduced glucagon rises after meals versus baseline.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon excursion
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
30 micro g t.i.d. · injection · 4 weeksAs given in this study (human).
Measurements
Postprandial glucagon excursion reduction (incremental AUC)
≈ 87%
after 4 weeks on pramlintide versus baseline
Source sentences
Summary
After 4 weeks on pramlintide, postprandial glucose, glucagon, and triglyceride excursions were reduced by approximately 86, approximately 87, and approximately 72%, respectively (incremental areas under the curve, all P < 0.05 vs. baseline).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265107
08HumanNon-randomized trialEfficacy outcome
In type 1 diabetes using insulin pumps, pramlintide reduced postprandial triglyceride excursions by approximately 72% versus baseline.
In plain wordsIn type 1 diabetes using insulin pumps, pramlintide reduced triglyceride rises after meals versus baseline.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial triglyceride excursion
Study
n = 16
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeksAs given in this study (human).
Measurements
Postprandial triglyceride excursion reduction (incremental AUC)
≈ 72%
after 4 weeks on pramlintide versus baseline
Source sentences
Summary
After 4 weeks on pramlintide, postprandial glucose, glucagon, and triglyceride excursions were reduced by approximately 86, approximately 87, and approximately 72%, respectively (incremental areas under the curve, all P < 0.05 vs. baseline).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265108
09HumanNon-randomized trialEfficacy outcome
In type 1 diabetes using insulin pumps, the glucose profile approached pretreatment values after pramlintide withdrawal.
In plain wordsIn type 1 diabetes using insulin pumps, glucose profiles approached baseline after pramlintide stopped.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableGlucose profile after withdrawal
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeks, followed by 2 weeks off treatmentAs given in this study (human).
Source sentences
Summary
At week 6 (off treatment), the 24-h glucose profile and postprandial glucose, glucagon, and triglyceride excursions approached pretreatment values.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265109
10HumanNon-randomized trialEfficacy outcome
In type 1 diabetes using insulin pumps, postprandial glucose excursions approached pretreatment values after pramlintide withdrawal.
In plain wordsIn type 1 diabetes using insulin pumps, glucose rises after meals approached baseline after pramlintide stopped.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableGlucose excursion after withdrawal
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeks, followed by 2 weeks off treatmentAs given in this study (human).
Source sentences
Summary
At week 6 (off treatment), the 24-h glucose profile and postprandial glucose, glucagon, and triglyceride excursions approached pretreatment values.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265110
11HumanNon-randomized trialMechanism
In type 1 diabetes using insulin pumps, postprandial glucagon excursions approached pretreatment values after pramlintide withdrawal.
In plain wordsIn type 1 diabetes using insulin pumps, glucagon rises after meals approached baseline after pramlintide stopped.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableGlucagon excursion after withdrawal
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
30 micro g t.i.d. · injection · 4 weeks, followed by 2 weeks off treatmentAs given in this study (human).
Source sentences
Summary
At week 6 (off treatment), the 24-h glucose profile and postprandial glucose, glucagon, and triglyceride excursions approached pretreatment values.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265111
12HumanNon-randomized trialEfficacy outcome
In type 1 diabetes using insulin pumps, postprandial triglyceride excursions approached pretreatment values after pramlintide withdrawal.
In plain wordsIn type 1 diabetes using insulin pumps, triglyceride rises after meals approached baseline after pramlintide stopped.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableTriglyceride excursion after withdrawal
Study
n = 16
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
30 micro g t.i.d. · injection · 4 weeks, followed by 2 weeks off treatmentAs given in this study (human).
Source sentences
Summary
At week 6 (off treatment), the 24-h glucose profile and postprandial glucose, glucagon, and triglyceride excursions approached pretreatment values.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 18 patients (16 of whom could be evaluated) with type 1 diabetes (age 44 +/- 11 years, HbA(1c) 8.2 +/- 1.3% [mean +/- SD]) were given mealtime injections of 30 micro g pramlintide t.i.d. for 4 weeks in addition to their preexisting CSII regimen (16 lispro, 2 regular insulin).
Report a problemFND-1250265112

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.